Tissue Regenix Group PLC HPRA approval & distribution agreement in Spain (6125R)
2023年10月30日 - 4:00PM
RNSを含む英国規制内ニュース (英語)
TIDMTRX
RNS Number : 6125R
Tissue Regenix Group PLC
30 October 2023
Tissue Regenix Group plc
('Tissue Regenix', the 'Company' or the 'Group')
HPRA approval & distribution agreement in Spain
HPRA approval to provide an Irish logistics hub for the
distribution of allograft products in the EU
New exclusive distribution agreement for Tissue Regenix's
allograft products in Spain
Tissue Regenix Group plc (AIM: TRX), the regenerative medical
devices company, announces that it has received approval from the
Irish Health Products Regulatory Authority ('HPRA'), allowing the
Company to set up a logistics hub in Ireland for the distribution
of its allograft products within the European Union ('EU').
The HPRA regulates medicines and devices in Ireland for the
benefit of people and animals, inspecting companies and facilities
which test, make or distribute health products to ensure that they
comply with relevant standards and legislation.
Tissue Regenix has also signed an exclusive distributor contract
with Spineart España SLU ('Spineart') for the distribution of its
allograft products in Spain. Spineart is a privately held medical
device company that operates in over 60 markets, focused on
simplifying surgery by designing, developing and promoting safe and
efficient solutions to spine surgeons, operating room teams and
patients.
Daniel Lee, Chief Executive Officer of Tissue Regenix,
commented: "Receiving HPRA approval is a great step for Tissue
Regenix, as it will provide a logistics hub for the distribution of
our allograft products to the European market. Following this, we
are delighted to be partnering with Spineart to bring our allograft
products to more customers in the EU. Spineart have a large global
footprint that we hope in time can be leveraged to bring our
products to more customers internationally."
For more information:
Tissue Regenix Group plc www.tissueregenix.com
David Cocke, Chief Financial Officer via Walbrook PR
Cavendish Capital Markets Limited (Nominated
Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore -
Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR and IR) Tel: +44 (0)20 7933 8780
Alice Woodings TissueRegenix@walbrookpr.com
About Tissue Regenix ( www.tissueregenix.com )
Tissue Regenix is a leading medical device company in
regenerative medicine. The Company's patented decellularisation
technology (dCELL(R)) removes DNA and other cellular material from
animal and human soft tissue, leaving an acellular tissue scaffold
not rejected by the patient's body that can be used to repair
diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle
injuries, and wound care.
In August 2017, Tissue Regenix acquired CellRight
Technologies(R). This biotech company specialises in regenerative
medicine and is dedicated to developing high-quality, innovative
tissue scaffolds to enhance healing opportunities in defects
created by trauma and disease. CellRight's human tissue products
may be used in spine, trauma, general orthopaedic, dental and
ophthalmological surgical procedures.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCKZMZGVNLGFZM
(END) Dow Jones Newswires
October 30, 2023 03:00 ET (07:00 GMT)
Tissue Regenix (LSE:TRX)
過去 株価チャート
から 4 2024 まで 5 2024
Tissue Regenix (LSE:TRX)
過去 株価チャート
から 5 2023 まで 5 2024